MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
5.62
+0.51
+9.98%
Closed 19:11 04/13 EDT
OPEN
5.11
PREV CLOSE
5.11
HIGH
5.71
LOW
5.11
VOLUME
87.87K
TURNOVER
0
52 WEEK HIGH
9.82
52 WEEK LOW
3.280
MARKET CAP
96.54M
P/E (TTM)
-3.3470
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VRCA last week (0406-0410)?
Weekly Report · 1d ago
Verrica late-breaking Phase 2 VP-315 data suggests abscopal effect in basal cell carcinoma
Reuters · 4d ago
Verrica Pharmaceuticals Reveals Acceptance Of A Late-breaking Abstract Reporting Phase 2 Exploratory Data Of VP-315; Data To Be Presented At The Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Benzinga · 4d ago
VERRICA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT HIGHLIGHTING POTENTIAL ABSCOPAL EFFECT OF VP-315 FOR THE TREATMENT OF BASAL CELL CARCINOMA AT THE UPCOMING 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING
Reuters · 4d ago
Verrica Pharma CEO to present at Needham Virtual Healthcare Conference
Reuters · 04/06 12:02
Weekly Report: what happened at VRCA last week (0330-0403)?
Weekly Report · 04/06 09:24
Weekly Report: what happened at VRCA last week (0323-0327)?
Weekly Report · 03/30 09:24
Weekly Report: what happened at VRCA last week (0316-0320)?
Weekly Report · 03/23 09:23
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.